multipl
sclerosi
ms
chronic
inflammatori
diseas
character
leukocyt
infiltr
subsequ
axon
damag
demyelin
inflamm
format
scleros
plaqu
brain
tissu
result
variou
studi
patient
indic
autoimmun
inflamm
make
import
impact
pathogenesi
ms
chemokin
key
mediat
inflamm
develop
cell
migrat
mediat
variou
immun
cell
respons
includ
chemotaxi
immun
activ
import
immun
inflamm
therefor
focu
chemokin
receptor
multipl
sclerosi
articl
summar
studi
role
promin
chemokin
receptor
ms
patient
ms
anim
modelsand
discuss
potenti
signific
inflammatori
injuri
repair
ms
also
summar
progress
treatment
multipl
sclerosi
antagonist
recent
year
chemokin
receptor
target
multipl
sclerosi
immunemedi
chronic
demyelin
disord
commonli
consid
result
interact
environment
genet
factor
still
unclear
common
neurolog
diseas
among
young
adult
meanwhil
major
caus
physic
disabl
among
young
adult
current
ms
phenotyp
classif
contain
rrm
ci
ppm
spm
mean
relapsingremit
multipl
sclerosi
clinic
isol
syndrom
primaryprogress
multipl
sclerosi
secondaryprogress
multipl
sclerosi
respect
among
rrm
account
major
patient
hallmark
ms
leukocyt
infiltr
brain
tissu
subsequ
axon
injuri
demyelin
inflamm
format
scleros
plaqu
abnorm
inflammatori
respons
initi
cell
promot
tissu
damag
cn
eae
ms
among
cell
cell
cell
domin
former
produc
latter
secret
gmcsf
granulocytemacrophag
colonystimul
factor
secret
substanc
enter
central
nervou
system
activ
astrocyt
microglia
produc
larg
number
chemokin
cytokin
recruit
peripher
immun
cell
site
inflamm
use
marker
identif
cell
reflect
proinflammatori
statu
also
reflect
abil
migrat
local
site
inflamm
initi
cell
entri
cn
govern
integrindepend
vascular
adhes
chemokinedriven
transbloodbrain
barrier
pathophysiolog
ms
fulli
understood
appear
autoimmun
activ
cellmedi
aggress
attack
one
key
mechan
cell
secret
cytokin
lead
activ
macrophag
cytotox
cytokin
produc
cell
lead
activ
b
cell
induct
antibodi
product
cytokin
inhibit
develop
cytokin
inhibit
respons
result
studi
indic
specif
immun
respons
contribut
pathogenesi
ms
diseas
inhibit
respons
protect
develop
ms
report
transit
cytokin
benefici
effect
clinic
cours
ms
although
research
pathogenesi
ms
focus
role
cell
fact
compar
anim
model
main
cell
found
central
nervou
system
ms
patient
cell
suggest
cell
may
play
import
role
human
diseas
grow
evid
indic
success
treatment
often
relat
chang
mani
lymphocyt
subpopul
includ
b
cell
nk
cell
lti
cell
ilc
cell
cell
nkt
cell
mait
cell
innat
b
cell
find
indic
multipl
lymphocyt
subpopul
involv
pathogenesi
diseas
also
identifi
cell
potenti
target
immunotherapi
classic
studi
anim
model
ms
allerg
encephalomyelitisexperiment
autoimmun
eae
virusinduc
model
toxininduc
demyelin
model
experiment
autoimmun
encephalomyel
abbrevi
eae
experiment
anim
model
human
ms
obtain
use
myelin
oligodendrocyt
protein
mog
proteolipid
protein
plp
myelin
basic
protein
mbp
immun
induc
certain
suscept
experiment
anim
mice
rodent
besid
eae
trigger
adopt
transfer
myelin
antigenspecif
cell
lymphocyt
type
cell
pathogenesi
eae
consist
two
phase
first
eae
prime
phase
dc
migrat
peripher
lymph
node
selfantigen
present
induc
encephalitogen
th
cell
second
point
enceph
th
cell
accumul
cn
reoccur
cognat
antigen
local
cnsinvas
apc
antigenpres
cell
homolog
antigen
patholog
characterist
experiment
autoimmun
encephalomyel
uniform
vari
wide
depend
type
anim
use
type
epitop
eae
model
relev
rrm
mostli
mog
induc
chronic
progress
diseas
closer
spm
mice
wherea
chronic
relapsingremit
diseas
nodlt
sjl
mice
lewi
rat
nonclass
chronic
relaps
eae
plj
mice
mog
immun
nod
mice
first
develop
acut
episod
eae
undergo
secondari
progress
eae
cours
model
use
simul
secondari
progress
diseas
ms
patient
da
dark
agouti
rat
recombin
rat
mog
use
induc
eae
character
demyelin
spinal
cord
injuri
subcutan
perivascular
inflammatori
infiltr
sjlj
mice
plp
induc
diseas
mimick
relapsingremit
eae
mbp
induc
acut
selflimit
chronic
recurr
diseas
progress
diseas
guinea
pig
cell
clone
reactiv
mbp
peptid
induc
eae
sjlj
mice
character
acut
paralysi
attack
mice
partial
fulli
recov
furthermor
spinal
cord
homogen
use
induc
eae
biozzi
abh
mice
recapitul
clinic
characterist
ms
includ
secondari
progress
disabl
relapsingremit
episod
address
role
adapt
immun
respons
neurodegener
mous
hepat
corona
viru
mhv
theiler
viru
tmev
two
wide
use
viral
induc
chronic
encephalomyel
ms
anim
model
system
exposur
anim
cuprizon
cpz
commonli
use
toxic
demyelin
model
demyelin
model
caus
focal
toxin
includ
focal
inject
lysolecithin
ethidium
bromid
specif
white
matter
tract
focal
inject
toxin
wide
use
ionomycin
diphtheria
toxin
spinal
cord
among
cpz
model
simul
acut
chronic
cours
ms
may
use
tool
develop
new
therapi
protect
oligodendrocyt
stimul
myelin
regener
tmev
infect
model
anim
model
special
studi
mechan
virusmedi
acut
primari
progress
ms
chemokin
regul
lymphoid
tissu
develop
lymphocyt
transport
home
leukocyt
matur
know
autoimmun
diseas
ms
character
uncontrol
inflammatori
state
increas
immun
cell
infiltr
tissu
parenchyma
upregul
express
chemokin
associ
elev
infiltr
macrophag
monocyt
lymphocyt
lesion
plaqu
level
specif
chemokin
ligand
continu
rise
result
sustain
infiltr
immun
cell
mani
chemokin
produc
local
tissu
attract
differ
kind
leukocyt
site
infect
inflamm
via
select
receptor
chemokin
could
induc
activ
leukocyt
adhes
molecul
establish
chemotact
concentr
gradient
caus
transendotheli
monolay
recruit
induct
proteolyt
enzym
promot
open
bbb
mediat
retent
leukocyt
central
nervou
system
chemokin
also
increas
adhes
migrat
target
cell
bbb
via
interact
leukocyt
integrin
exampl
autoreact
cell
target
myelin
compon
trigger
ms
diseas
vital
step
transport
inflammatori
cell
cn
ms
lot
report
analyz
role
chemokin
chemokin
receptor
intrathec
accumul
cell
ms
chemokin
small
protein
conserv
sequenc
structur
featur
usual
amino
acid
residu
typic
kda
mw
molecular
weight
human
mammalian
genom
encod
approxim
chemokin
respect
chemokin
contain
four
cystein
residu
natur
divid
four
class
accord
structur
charact
space
first
two
cystein
residu
cc
cxc
c
first
three
subfamili
two
cystein
residu
space
residu
separ
xc
subfamili
second
cystein
residu
exist
systemat
name
chemokin
consist
prefix
like
ccl
cxcl
cl
follow
identifi
number
chemokin
receptor
name
accord
group
chemokin
bind
therefor
systemat
name
consist
prefix
like
ccr
cxcr
cr
follow
identif
number
system
nomenclatur
l
signifi
ligand
r
denot
receptor
exampl
name
base
rule
besid
criteria
chemokin
may
categor
accord
biolog
role
inflammatori
chemokin
activ
upregul
inflammatori
condit
role
respons
tissu
damag
infect
physiolog
abnorm
adapt
innat
immun
includ
express
temporari
resolut
situat
homeostat
chemokin
express
lymphoid
organ
constitut
includ
mediat
homeostat
migrat
home
differ
cell
contain
lymphocyt
need
proper
function
immun
system
addit
development
process
relat
pattern
cell
complex
movement
often
involv
homeostat
chemokin
also
third
class
bifunct
chemokin
elev
case
inflammatori
condit
particip
normal
immun
defens
group
includ
etc
chemokin
critic
mediat
inflamm
develop
cell
migrat
routin
immun
surveil
secret
activ
lymphocyt
regul
accumul
migrat
monocytesmacrophag
lymphocyt
damag
cn
district
promot
differenti
therefor
maintain
immun
respons
process
chemokin
receptor
subfamili
rhodopsin
gpcr
g
proteincoupl
receptor
famili
includ
member
angiotensin
somatostatin
fmlp
bradykinin
adrenomedullin
receptor
admr
great
major
chemokin
bind
activ
multipl
receptor
turn
great
major
chemokin
receptor
respond
one
chemokin
chemokin
bind
gpcr
chemokin
receptor
precis
caus
conform
chang
touch
intracellular
signal
pathway
involv
cell
activ
movement
thu
mediat
variou
leukocyt
respons
includ
chemotaxi
immun
activ
differ
chemokinechemokin
receptor
repres
differ
immun
respons
type
featur
immun
respons
featur
immun
respons
addit
highli
express
cell
highli
express
cell
human
mice
chemokin
receptor
differ
express
level
memori
cell
effector
cell
subset
provid
specif
cell
traffick
homeostasi
inflamm
direct
cell
cn
inhibit
cell
migrat
migrat
naiv
cell
central
memori
cell
peripher
lymph
node
small
moleculemedi
upregul
amelior
eae
role
initi
stage
diseas
provid
promis
strategi
effect
diseas
therapi
develop
ms
cn
white
matter
trauma
ms
acut
eae
show
high
level
involv
aggreg
activ
leukocyt
express
receptor
cc
class
chemokin
largest
four
chemokin
consist
least
chemokin
member
signal
cc
chemokin
chemotact
effect
monocyt
lymphocyt
subset
also
stimul
eosinophil
basophil
natur
killer
cell
chemokin
receptor
bind
cc
class
chemokin
mainli
express
monocytemacrophag
cell
cell
type
relat
chronic
inflamm
multipl
sclerosi
persist
leukocyt
infiltr
site
inflamm
also
known
potent
chemokin
recruit
process
macrophag
monocyt
activ
cell
nk
cell
cn
mcp
import
member
cc
subfamili
date
five
mcp
identifi
classifi
mean
among
mcp
first
one
discov
characterist
cc
subclass
chemokin
human
produc
cell
endotheli
cell
astrocyt
macrophag
microglia
one
studi
show
efflux
may
mediat
astrocyt
abc
transport
pglycoprotein
therebi
promot
migrat
immun
cell
across
brain
endotheli
cell
involv
process
neuroinflamm
crucial
induct
acut
eae
determin
five
mcp
play
role
interact
receptor
due
highest
affin
studi
focus
two
altern
splice
type
human
amino
acid
respect
express
cell
subset
immatur
dendrit
cell
monocyt
mediat
migrat
endogen
cc
chemokin
endogen
ligand
human
worth
note
first
six
agonist
last
two
antagonist
endogen
ligand
mice
rat
http
guidetopharmacologyorggrac
objectdisplayforward
objectid
access
septemb
level
cn
reduc
increas
diseas
activ
ms
accord
discoveri
franciotta
et
al
constitut
produc
brain
csf
level
acut
ms
lower
stabl
ms
demonstr
gdenhanc
lesion
mri
rrm
patient
acut
exacerb
significantli
lower
level
csf
serum
without
enhanc
lesion
howev
anoth
studi
result
determin
higher
level
csf
patient
rrm
compar
control
differ
studi
may
due
differ
popul
differenti
product
unequ
stage
diseas
rare
use
healthi
control
differ
compon
control
group
studi
ms
relaps
shown
induc
depress
cytokin
predomin
affect
cell
differenti
adjust
cytokin
profil
thu
decreas
level
csf
might
reflect
increas
activ
acut
episod
mrna
express
level
dramat
increas
spinal
cord
brain
protein
express
level
significantli
upregul
brain
relaps
phase
ms
express
biolog
relev
function
relaps
eae
diseas
process
due
abil
improv
relaps
clinic
diseas
treatment
inhibit
relaps
eae
relev
decreas
influx
macrophag
data
demonstr
level
cn
protein
product
low
preclin
mice
diseas
rise
mog
induc
sharpli
initi
clinic
symptom
develop
acut
diseas
peak
hulkow
et
al
demonstr
mrna
express
close
tempor
relat
symptom
onset
cn
rat
also
note
mrna
could
longer
detect
anim
enter
remiss
reason
hypothesi
encephalitogen
cell
secret
certain
proinflammatori
cytokin
contain
ifng
tnfa
abl
induc
astrocyt
express
rant
etc
lead
recruit
addit
mononuclear
cell
upregul
activ
oligodendrocyt
progenitor
near
demyelin
region
possibl
differenti
matur
myelin
form
oligodendrocyt
enhanc
activ
oligodendrocyt
progenitor
cell
therebi
allow
remyelin
play
role
regionspecif
manner
cuprizoneinduc
demyelin
mice
astrocyt
activ
special
effect
gray
matter
addit
current
ms
therapi
treatment
modifi
circul
level
known
proport
high
cell
cn
posit
correl
eae
clinic
score
recruit
proinflammatori
high
monocyt
subpopul
involv
chemokin
addit
mice
illustr
cn
histopatholog
clinic
eae
mog
induc
mice
decreas
obvious
cell
infiltr
compar
control
mice
recent
evid
suggest
highli
phagocyt
inflammatori
macrophag
produc
bloodderiv
rfp
monocyt
elicit
demyelin
eae
accord
nielsen
etal
assess
demyelin
effect
monocyt
cortic
show
th
mice
develop
eae
later
th
mice
sever
compar
importantli
perivascular
cortic
subpial
demyelin
mog
induc
mice
th
mice
significantli
reduc
compar
th
mice
ga
polymorph
might
elev
suscept
multipl
sclerosi
effect
appear
limit
individu
primari
risk
allel
includ
gamma
produc
variou
cell
especi
macrophag
lymphocyt
dendrit
cell
protein
act
b
cell
cell
dc
eosinophil
best
known
chemotaxi
proinflammatori
effect
also
promot
homeostasi
detail
function
chemotaxi
phagocyt
synthesi
inflammatori
mediat
degranul
target
cell
acut
phase
inflamm
activ
recycl
leukocyt
effect
chemokin
lymphocyt
monocyt
one
uniqu
featur
abil
coordin
compartment
mobil
mpc
myeloid
precursor
cell
preclin
studi
demonstr
releas
induct
respons
express
great
amount
leukocyt
includ
dendrit
cell
monocyt
nk
cell
cell
basophil
eosinophil
consid
target
ms
due
observ
perivascular
stain
immunohistochem
studi
biopsi
deceas
chemokin
receptor
strongli
express
brain
inflammatori
foci
patient
studi
mohammad
soleimani
et
al
found
obviou
increas
csf
level
rmss
patient
compar
control
group
eltayeb
et
al
found
use
dna
vaccin
protocol
gener
immunolog
neutral
antibodi
effect
inhibit
diseas
induct
da
rat
eae
mog
induc
delet
gene
result
partial
diseas
protect
ms
mous
model
data
provid
strong
argument
macrophag
activ
critic
neuroinflammatori
process
eae
also
name
rant
marker
macrophag
infiltr
cell
abl
express
secret
chemokin
mainli
express
perivascular
cell
vascular
endotheli
cell
astrocyt
possibl
adjust
glutam
releas
plastic
ms
brain
associ
effect
diseas
clinic
manifest
detect
activ
demyelin
ms
lesion
receptor
strong
monocyt
chemotaxi
mainli
express
immatur
dendrit
cell
cell
small
number
monocyt
express
monocyt
macrophag
cell
inflammatori
ms
lesion
two
way
involv
pathogenesi
ms
one
increas
number
cell
circul
ms
patient
monocyt
phagocytosi
function
greatli
enrich
express
csf
peripher
blood
research
e
sindern
et
al
detect
csf
rrm
releas
serum
increas
howev
studi
mori
f
et
al
includ
rrm
patient
level
higher
csf
patient
control
group
increas
ms
diseas
activ
one
research
et
al
confirm
presenc
elev
cerebrospin
fluid
patient
acut
ms
fact
lymphocyt
express
activ
ms
lesion
autopsi
brain
tissu
piec
evid
suggest
role
develop
ms
mice
infect
mous
hepat
viru
mhv
brain
reproduc
result
acut
encephalomyel
develop
chronic
demyelin
diseas
chronic
diseas
stage
neuropatholog
primarili
immunemedi
similar
human
demyelin
diseas
ms
multipl
sclerosi
use
anim
model
significantli
express
cn
acut
diseas
mabmedi
neutral
result
delay
viral
clearanc
concomit
reduct
migrat
virusspecif
cell
activ
macrophag
cell
macrophag
infiltr
decreas
demyelin
decreas
experi
show
contribut
macrophag
entri
demyelin
howev
anoth
anim
model
eae
model
ms
immunolog
neutral
modul
effect
use
dna
vaccin
protocol
gener
immunoneutr
antibodi
also
fail
inhibit
diseas
induct
rat
eae
mog
induc
da
rat
genom
delet
also
protect
eae
mice
impact
genet
polymorph
high
produc
allel
relev
wors
progress
ms
disabl
low
produc
allel
associ
decreas
risk
sever
axon
loss
express
may
disrupt
gene
mutat
downregul
receptor
exampl
genet
polymorph
ie
singl
nucleotid
substitut
g
posit
gene
promot
result
lower
express
posit
receptor
promot
sequenc
base
pair
delet
gene
code
region
associ
lower
ms
sever
index
although
signific
increas
express
found
ms
patient
appear
besid
mutat
haplotyp
polymorph
well
possibl
epigenet
genet
factor
vital
express
multipl
sclerosi
patient
addit
base
summari
one
review
appear
consensu
associ
mutat
ms
differ
report
may
reflect
genet
background
studi
popul
exposur
environment
factor
also
call
altern
macrophag
activ
associ
cc
chemokin
pulmonari
activationregul
chemokin
parc
one
specif
marker
macrophag
highest
chemokin
express
level
sever
human
chronic
inflammatori
diseas
synthes
dendrit
cell
monocyt
infect
inflamm
function
attract
cell
induc
regulatori
cell
phenotyp
may
import
factor
inhibit
local
proinflammatori
immun
respons
cn
level
correl
neurodegen
inflammatori
brain
mri
result
level
higher
progress
multipl
sclerosi
compar
healthi
individu
rrm
variou
correl
mri
measur
discov
higher
level
relat
decreas
dgm
deep
grey
matter
ncv
normal
cortic
volum
thalam
volum
increas
lesion
volum
lvv
later
ventricular
volum
shred
evid
support
function
progress
ms
correl
level
edss
expand
disabl
statu
scale
well
diseas
durat
found
howev
anoth
studi
suggest
inhibit
chemotaxi
identifi
one
top
upregul
gene
verg
chronic
activ
ms
lesion
larg
amount
foam
microgliamacrophag
accumul
myelin
consist
previou
research
boven
la
et
al
recruit
subset
human
regulatori
cell
inhibit
prolifer
effector
cell
product
vitro
express
macrophag
also
ingest
myelin
produc
immunosuppress
phenotyp
incub
microglia
dexamethason
result
signific
upregul
consid
antiinflammatori
factor
produc
mani
kind
cell
includ
endotheli
cell
macrophag
respond
stimuli
attract
lymphocyt
attract
monocyt
express
site
call
choroid
plexu
cell
enter
cn
receptor
select
express
cell
produc
cytokin
thu
interact
involv
bbb
disrupt
followup
migrat
pathogen
cell
cn
moreov
secret
circul
cell
expand
proinflammatori
respons
via
signal
enhanc
transcript
one
studi
el
sharkawi
fz
et
al
serum
level
patient
spm
rrm
obvious
higher
healthi
subject
trend
ident
result
research
serum
level
rrm
patient
control
li
r
et
al
well
result
higher
serum
level
patient
spm
rrm
ppm
studi
jafarzadeh
et
al
studi
also
show
serum
level
associ
progress
index
show
higher
remiss
period
relaps
treatment
type
influenc
chemokin
level
also
consist
previou
research
result
howev
serum
level
higher
remiss
relaps
significantli
accord
kalinowskalyszczarz
et
al
one
studi
show
neg
correl
activ
level
serum
level
patient
specul
may
downregul
transcript
activ
deacetyl
promot
region
gene
therebi
decreas
express
specul
requir
research
prove
serum
level
affect
diseas
pattern
gender
treatment
option
research
found
level
invers
associ
clinic
sever
eae
ms
patient
lower
antibodi
level
healthi
control
moreov
high
level
antibodi
human
serum
biolog
activ
inhibit
posit
cell
migrat
base
experiment
result
abraham
et
al
hypothes
natur
vaccin
protect
human
autoimmun
ms
develop
suppos
exposur
pathogen
earli
life
might
result
product
autoantibodi
trigger
protect
effect
ms
develop
research
jafarzadeh
et
al
express
level
spinal
cord
eae
mice
mog
induc
mice
administ
pb
evid
elev
compar
control
group
result
studi
concomit
effect
singl
nucleotid
polymorph
snp
c
ms
suscept
show
ct
genotyp
frequenc
gene
c
allel
frequenc
multipl
sclerosi
patient
obvious
higher
control
group
accompani
polymorph
gene
ms
patient
egypt
show
increas
risk
ms
rather
individu
locu
anoth
studi
iran
show
polymorph
associ
spm
model
chemokin
accumul
movement
cell
contain
cell
site
inflamm
produc
microglia
astrocyt
macrophagederiv
chemokin
produc
monocytederiv
dendrit
cell
macrophag
upon
stimul
antibodi
microbi
product
downregul
type
cytokin
upregul
type
cytokin
identifi
one
risk
gene
ms
found
treg
cell
particular
marker
cell
sinc
cell
produc
antiinflammatori
cytokin
particip
accumul
subset
cell
antiinflammatori
function
brain
regulatori
cell
suggest
may
involv
counteract
proinflammatori
respons
ultim
lead
reduc
degre
myelin
damag
decreas
serum
level
report
multipl
sclerosi
patient
research
level
csf
women
higher
men
may
effect
ms
develop
women
affect
brain
recruit
cell
produc
antiinflammatori
cytokin
studi
women
ms
patient
show
lower
serum
level
repres
decreas
chemokin
level
might
great
impact
ms
pathogenesi
women
compar
ond
patient
noninflammatori
neurolog
diseas
csf
level
evid
increas
ms
patient
baselin
trend
decreas
allel
ca
snp
put
forward
ms
patient
compar
control
group
may
primarili
attract
treg
cell
shut
adapt
immun
respons
effect
express
level
spinal
cord
eae
mice
mog
induc
mice
significantli
increas
express
relat
increas
sever
eae
treatment
may
improv
eae
develop
possibl
regul
inflammatori
macrophag
accumul
cxcl
subfamili
chemokin
divid
elr
elr
posit
group
elrv
elr
neg
group
former
characterist
threesequ
elr
gluleuarg
latter
elr
chemokin
eg
combin
typic
attract
neutrophil
activ
neutrophil
degranul
caus
releas
myeloperoxidas
enzym
elr
neg
cxc
chemokin
includ
combin
control
chemotaxi
lymphocyt
togeth
xcl
chemokin
rumbl
jm
et
al
demonstr
first
time
peak
level
plasma
elr
cxc
chemokin
consist
develop
new
inflammatori
lesion
relaps
ms
patient
also
demonstr
express
associ
radiolog
clinic
measur
cn
lesion
ms
express
inflammationinduc
receptor
endothelium
increas
ms
plaqu
haarmann
et
al
demonstr
interfer
endotheli
cell
membran
barrier
morpholog
function
via
inhibit
brain
endotheli
cell
prevent
decomposit
bbb
eae
directli
affect
vascular
permeabl
oligodendrocyt
lineag
cell
neutrophil
cn
express
neutrophil
promot
inflammatori
demyelin
first
chemokin
receptor
show
contribut
control
remyelin
inflammatori
process
caus
demyelin
effect
chemoattract
immun
cell
interact
receptor
also
bind
atyp
chemokin
receptor
migrat
b
cell
cell
block
use
neutral
antibodi
vitro
elev
inact
activ
ms
lesion
well
astrocyt
ms
patient
report
found
ms
patient
higher
csf
level
healthi
subject
chemokin
receptor
prove
vital
life
constitut
express
variou
tissu
found
mani
kind
cell
microglia
astrocyt
neuron
naiv
cell
effector
cell
vascular
endotheli
cell
human
brain
mutant
shown
antagonist
ident
human
except
prolin
replac
glycin
posit
two
data
kohler
et
al
show
effect
inhibit
migrat
activ
mous
cell
interfer
action
synthet
receptor
antagonist
inhibit
eae
plp
induc
sjlj
mice
reduc
accumul
encephalitogen
cell
cn
thu
inhibit
sensit
phase
eae
involv
local
cell
cn
inhibit
effector
phase
immun
respons
thu
target
might
benefici
cn
autoimmun
diseas
treatment
b
cell
chemokin
also
known
b
lymphocyt
chemoattract
blc
b
cell
attract
chemokin
infiltr
macrophagesdc
myeloid
cell
microglia
may
one
sourc
central
nervou
system
inflamm
addit
cell
found
brainstem
mening
strong
infiltr
leukocyt
prolifer
f
sellebjerg
et
al
found
csf
concentr
correl
csf
leukocyt
count
significantli
patient
rrm
ppm
ci
spm
even
stronger
csf
bcell
count
patient
ci
rrm
addit
b
cell
direct
correl
cerebrospin
fluid
ms
patient
level
number
plasmablast
cell
khademi
et
al
determin
concentr
csf
healthi
control
popul
patient
ms
neurolog
diseas
bacteri
viral
infect
result
show
lesser
extent
rise
ms
patient
taken
togeth
believ
earli
detect
predict
diseas
prognosi
express
b
cell
csf
compart
b
cell
blood
cell
csf
blood
defici
attenu
glial
hyperplasia
inflamm
white
matter
acut
chronic
phase
eae
indic
improv
condit
result
reflect
may
bind
thu
may
involv
recruit
mononuclear
cell
express
intrathec
compart
ms
level
reduc
natalizumab
treatment
ms
accord
quinn
jl
et
al
antibodi
could
block
tfh
transport
significantli
reduc
diseas
express
eae
eae
induc
myelinspecif
cell
transfer
j
mice
famili
one
member
atyp
chemokin
membranebound
type
solubl
form
abl
act
effect
adhes
molecul
chemoattract
nonintegrindepend
mechan
also
known
fractalkin
amino
acid
neuron
chemokin
bodi
proinflammatori
antiinflammatori
neuroprotect
effect
brain
express
neuron
cell
stimul
microglia
astrocyt
also
produc
also
express
activ
endotheli
cell
ec
locat
surfac
caviti
indic
arrest
circul
cell
ec
membran
promot
glial
activ
express
proinflammatori
cytokin
secret
recruit
cell
cn
neuroinflammatori
process
exist
two
form
shed
glycoprotein
membran
anchor
former
solubl
form
chemotact
activ
monocyt
cell
nk
cell
combin
gpcr
gprotein
coupl
receptor
express
microglia
astrocyt
dendrit
cell
dc
nk
cell
monocyt
b
cell
cell
subset
level
elev
csf
ci
patient
cerebrospin
fluid
serum
sampl
rrm
patient
earli
inflammatori
respons
multipl
sclerosi
induc
accumul
cell
cn
result
broux
b
et
al
show
cell
migrat
inflamm
site
responsd
chemotact
gradient
contribut
inflammatori
process
ms
patient
choroid
plexu
barrier
cerebrospin
fluid
blood
brain
main
entri
site
immun
cell
enter
central
nervou
system
induc
choroid
plexu
eae
result
show
block
prevent
develop
eae
inhibit
lymphocyt
across
cn
block
protect
mice
eae
invas
data
wenjun
zhu
et
al
show
signal
dorsal
horn
sc
neuron
activ
upregul
pathway
involv
nocicept
transmiss
earli
inflammatori
phase
premyelin
ms
moginduc
eae
da
rat
associ
cell
express
mrna
clearli
accumul
inflammatori
brain
injuri
vast
major
cell
microgliamacrophag
lineag
cell
accumul
cell
microglia
indic
may
particip
control
invas
peripher
leukocyt
brain
nk
cell
obvious
reduc
inflam
cn
eae
mice
mog
plp
induc
mice
monocytesmacrophag
cell
nkt
cell
recruit
cn
eae
requir
chemic
attract
nk
cell
rel
specif
cn
arli
b
et
al
believ
vi
receptor
haplotyp
may
protect
effect
convers
spm
receptor
haplotyp
genotyp
ii
patient
higher
risk
disabl
studi
chemokin
receptor
antagonist
offer
potenti
lead
compound
treatment
ms
well
deep
understand
pathogenesi
eae
antiinflammatori
effect
may
due
inhibit
chemotaxi
therebi
prevent
leukocyt
flow
affect
tissu
follow
method
modul
chemokin
receptor
peptid
antagonist
neutral
antibodi
small
nonpeptidyl
antagonist
immunoneutr
specif
chemokin
provid
inform
receptor
import
commonli
interact
divers
chemokin
receptor
case
combin
perspect
therapeut
mechanist
meaning
administ
select
low
molecular
drug
inhibit
effect
effect
chemokin
receptor
acut
eae
ms
induct
phase
autoimmun
respons
take
redund
chemokin
express
patholog
account
prefer
select
compound
block
multipl
inflammatori
chemokin
receptor
simultan
one
chemokin
receptor
mediat
monocyt
traffick
site
inflamm
stimul
particularli
import
control
earliest
proinflammatori
event
border
zone
inflammatori
brain
injuri
activ
ms
advanc
eae
interf
activ
vivo
specif
antibodi
genom
delet
gene
result
signific
reduct
paralyt
diseas
first
select
antagonist
enter
clinic
trial
berlex
bioscienc
consider
effect
oral
administ
antagonist
express
rrm
patient
fail
phase
ii
trial
efficaci
lack
lay
foundat
clinic
develop
chemokin
receptor
antagonist
highthroughput
screen
merritt
jr
et
al
combinatori
seri
identifi
new
moder
effect
antagonist
librari
hit
optim
order
synthesi
advanc
lead
compound
therefor
compound
obtain
compound
inhibit
monocyt
chemotaxi
nm
result
studi
show
although
antagonist
stop
peripher
antimog
respons
da
rat
prevent
cell
infiltr
effect
macrophag
infiltr
activ
therebi
prevent
subsequ
cn
inflamm
model
singl
select
antagonist
suppress
moginduc
eae
indic
play
nonredund
role
stage
mani
therapi
current
target
leukocyt
traffick
inflamm
cn
target
drug
enter
ms
past
gener
shown
favor
safeti
profil
clinic
trial
fail
efficaci
involv
clinic
research
current
classic
competit
antagonist
great
quantiti
multiqsar
model
techniqu
eg
pharmacodynam
map
comfa
etc
perform
data
set
consist
eightythre
antagonist
design
higher
activ
molecul
sk
abdul
amin
et
al
design
seven
new
molecul
expect
activ
best
activ
antagonist
seri
cpd
extracellular
loop
verso
nativ
acid
peptid
inhibitor
select
potent
inhibit
trigger
chemotaxi
alloster
antagon
human
mous
kind
human
antibodi
show
efficaci
patient
multipl
sclerosi
although
administr
reduc
circul
monocyt
number
peripher
blood
small
molecul
antagonist
therapeut
dose
significantli
reduc
clinic
symptom
diseas
eae
mice
mog
induc
mice
diseas
incid
sever
buntinx
et
al
identifi
noncompetit
potent
antagonist
exert
antiinflammatori
activ
mice
express
transgen
mgkg
qd
treatment
delay
onset
reduc
sign
nervou
system
eae
temporarili
significantli
howev
piec
evid
diseas
improv
long
term
therefor
author
say
use
may
success
ms
patient
merck
corpor
disclos
number
antagonist
contain
compound
ic
nm
indic
potent
antagonist
activ
undergon
clinic
trial
ms
primari
endpoint
trail
new
gdenhanc
lesion
mri
enter
phase
ii
clinic
trial
ms
improv
significantli
compar
placebo
incyt
also
exploit
varieti
antagonist
one
compound
phase
ii
clinic
research
ms
subsequ
report
trial
result
lagumersindezdeni
n
et
al
hypothes
target
may
effect
treatment
strategi
cortic
demyelin
develop
kind
novel
mous
antihuman
monoclon
antibodi
aim
deplet
monocyt
compar
isotypetr
control
monocytedeplet
anim
reveal
less
perivascular
type
cortic
demyelin
less
subpial
type
cortic
demyelin
significantli
line
amelior
clinic
diseas
cours
mainli
express
treg
lymphocyt
antagonist
classifi
two
categori
aryl
sulphonamid
lipophil
heteroaren
small
molecul
antagonist
like
endogen
ligand
also
shown
differ
abil
induc
receptor
intern
may
relev
differ
biolog
effect
antagonist
combin
alloster
site
bind
site
ligand
may
reason
antagonist
compound
inhibit
cell
polar
well
amelior
eae
antagonist
signific
impact
clinic
score
eae
optimist
antagonist
test
approv
ms
treatment
exampl
phase
clinic
trial
one
kind
antagonist
gsk
possibl
treatment
asthma
still
develop
due
low
bioavail
condit
might
caus
complex
pharmacolog
resolv
regul
surfac
express
transport
aspect
mice
mog
induc
mice
report
exhibit
lowgrad
eae
symptom
express
cell
immatur
dendrit
cell
langerhan
cell
uniqu
chemokin
receptor
combin
chemokin
exclus
defici
mice
high
resist
eae
mog
induc
mice
induc
mog
immun
addit
doubl
knockout
mice
show
low
degre
eae
sever
mog
induc
mice
number
cn
infiltr
cell
knockout
mice
obvious
decreas
compar
wild
type
mice
cell
highli
express
addit
dendrit
cell
b
cell
cell
subpopul
also
express
major
chemokin
induc
immun
cell
recruit
cn
interact
correspond
receptor
initi
studi
shown
gene
target
disrupt
affect
sever
eae
maraviroc
celsentri
tm
first
antagonist
approv
treatment
infect
ema
european
medicin
agenc
togeth
approv
use
antagonist
larg
number
clinic
trial
small
molecul
biolog
current
underway
reflect
belief
chemokin
system
serv
therapeut
target
treatment
develop
eae
diseas
follow
influenza
infect
may
mediat
type
cell
infiltr
cn
administr
antagonist
significantli
amelior
exacerb
eae
ridderstad
wollberg
et
al
demonstr
express
mrna
inflammatori
cell
activ
plaqu
region
ms
brain
autopsi
inhibitor
effect
outsid
cn
order
verifi
function
pathogenesi
ms
treat
dark
agouti
rat
moginduc
eae
led
reduc
cn
patholog
paralysi
recurr
effect
acut
phase
et
al
exploit
two
parallel
seri
seri
seri
b
antagonist
ms
treatment
modifi
pyrimidin
develop
first
select
potent
oral
antagonist
block
leukocyt
outsid
cn
could
anoth
altern
approach
treat
multipl
sclerosi
onset
ms
close
relat
immun
dysfunct
demonstr
inflamm
oligodendrocyt
death
loss
myelin
variou
degre
axon
damag
format
ms
plaqu
begin
antigenpres
cell
activ
myelinreact
lymphocyt
result
multifoc
immun
cell
infiltr
cn
see
fig
inflammatori
infiltr
cell
activ
demyelin
lesion
cell
macrophag
resid
microglia
infiltr
monocyt
activ
immun
cell
activ
proinflammatori
cytokin
cascad
cn
ultim
lead
demyelin
glial
scar
axon
lesion
regul
immun
respons
cell
infiltr
cn
therapeut
strategi
improv
treatment
efficaci
role
chemokin
receptor
autoimmun
inflamm
recogn
also
import
impact
normal
homeostasi
includ
lymphoid
tissu
develop
cell
transport
chemokin
system
rich
ligand
receptor
studi
shown
lot
chemokin
receptor
effect
therapeut
target
ms
diseas
specif
interf
chemokin
chemokin
receptor
function
prevent
infiltr
inflammatori
cell
control
cascad
inflamm
may
also
prevent
demyelin
damag
promot
remyelin
bring
new
treatment
ms
hope
howev
develop
singl
chemokin
receptor
antagonist
achiev
imaginari
success
overcom
redund
chemokin
action
develop
multitarget
antagonist
combin
multipl
antagonist
may
futur
direct
ms
drug
develop
